Role of Radiation in Combination With CD30-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma: Bridging and Salvage RT for Hodgkin Lymphoma

CD30-directed Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment option for patients with relapsed/refractory Hodgkin lymphoma (R/R HL) with phase 1/2 trials showing favorable tolerability and clinical efficacy. However, unlike the extensive literature supporting bridging radiation for large B-cell lymphoma (LBCL), there is a dearth of literature on the use of radiation therapy combined with CAR T-cell therapy for R/R HL. Here, we present two patients with R/R HL receiving CD30-directed CAR T-cell therapy; one received bridging (bRT) and salvage radiation and the other received salvage radiation alone.